with @vijaypande, @julesyoo, and @hannetidnam Aall about what exactly virtual care and “telemedicine” is... and what it isn’t; what it works well for, what doesn’t (yet), and where there’s potential; and finally, the current pain points (including regulation), and what we’ll learn from this current moment for the next generation of virtual medicine tools.

with Dave King, @JorgeCondeBio, and @omnivorousread In this episode with Dave King, Executive Chairman of Lab Corp (one of the largest clinical lab networks in the world) and a16z's General Partner Jorge Conde and Hanne Tidnam, we cover the evolution of the modern lab over the past 50 years, especially as new technologies and new tests are added; how tests go from specialized to mainstream and widely available; and who pays for most tests and how reimbursement affects all this.

with @kimbatronic @jesswldn @zoranbasich We open up and share an internal, hallway style (though all remote) conversation about how a16z Crypto Startup School suddenly had to go remote, given community spread of the novel coronavirus. How are we learning about virtual learning and collaboration in a new, uncharted world?

with @illscience @DCoolican & @laurenmurrow While revealing one's financial info was once considered taboo, now people are more apt than ever to openly discuss money and debt on online platforms (#debtfreejourney). In this episode, we discuss why the "holy grail" of social plus fintech is so challenging, which products and companies are taking advantage of it, and how that shift is being driven by subcultures online.

with @nicolefv @jezhumble @smc90 One of the recurring themes we talk about a lot is how software changes organizations, and vice versa. But we've come a long way from the question of "does IT matter" to answering the question of what org structures, processes, architectures, and roles DO matter when it comes to companies -- of all sizes -- innovating through software and more.

Red Hat CIO Mike Kelly and a16z General Partner Peter Levine discuss the latest trends in open source SaaS and what CIOs today need to be considering, from enterprise architecture models to M&A.

This is last week's episode of 16 Minutes on the news from a16z, which we are cross-posting here now -- with most recent updates added in the intro -- given that the topic of *health system preparedness* and community spread is top of mind for many right now.

with @andrewchen @jeff_jordan @smc90 What happens as marketplaces and other platforms evolve over time, and different kinds of users also join over time? After user acquisition, it's all about user retention and engagement. So what are the key metrics?

Susan Rice is interviewed by a16z General Partner Kathryn Haun. Rice, the former National Security Advisor and U.S. Ambassador to the U.N., learned early in life the importance of toughness in the face of adversity. In this discussion, she shares many more lessons from her personal life and career, including how to stay calm during crises, not letting others define you, and work-life balance.

CAR T therapy, the groundbreaking new medicines that uses engineered T-cells to attack cancer, has been so effective in childhood leukemias that we believe it may actually be a potential cure. But this isn't just one new medicine, it's an entirely new therapeutic tool—and a total paradigm shift from most traditional medicines we've seen before.

with @francescagino and @omnivorousread In this episode of the a16z Podcast, Harvard Business School Professor Francesca Gino, a social scientist who studies organizations, breaks down what makes rebels different in how they tend to see and do things—whether that’s cooking, flying planes, or holding board meetings—and what we can all learn from “rebel talent” to make our organizations more productive and innovative.

with @heyjudka @smc90 This episode of 16 Minutes on the news from a16z (cross-posted here as well) covers what we know and what we don't know about the recent coronavirus outbreak 2019-nCoV. Topics covered include the what, when, how -- and where genomics comes in.

The idea of "1000 true fans" argued that to be a successful creator, you don’t need millions of customers or clients, as long as you also have a direct relationship with those fans. But how is media changing today as a result, and what nuances do people often miss about the concept? And why are we apparently surrendering our attention (whether to TV, books, or whatever) for only $3 an hour?!

with @cjgbest @robertcottrell @andrewchen @smc90 A new ecosystem is forming around the direct relationship between consumers, content creators, and the tools and business models to facilitate all that. We're not just seeing this phenomenon in newsletters and podcasting, but also in people setting up e-commerce shops, video streaming, and more. Are the stars and the incentives finally aligned?

Chris Dixon, a16z General Partner, is interviewed by Jonah Peretti, founder and CEO of Buzzfeed. They discuss all things internet, including how innovation comes about, the ways disparate trends collide, and more.

AI can do a lot of specific tasks as well as, or even better than, humans can — for example, it can more accurately classify images, more efficiently process mail, and more logically manipulate a Go board. While we have made a lot of advances in task-specific AI, how far are we from artificial general intelligence (AGI), that is AI that matches general human intelligence and capabilities? In this podcast, a16z operating partner Frank Chen interviews Stuart Russell, Founder of the Center for Human-Compatible Artificial Intelligence (CHAI) at UC Berkeley. They outline the conceptual breakthroughs, like natural language understanding, still required for AGI. But more importantly, they explain how and why we should design AI systems to ensure that we can control AI, and eventually AGI, when it’s smarter than we are. The conversation starts by explaining what Hollywood's Skynet gets wrong and ends with why AI is better as "the perfect Butler, than the genie in the lamp."

The federal agency known as the FDA, or the Food and Drug Administration, was born over 100 years ago—at the turn of the industrial revolution, in a time of enormous upheaval and change, and rapidly emerging technology. The same could be said to be just as true today. This wide-ranging conversation between Principal Commissioner of the FDA Amy Abernethy and Vijay Pande, GP on the Bio Fund at a16z, discusses how the agency is evolving to keep pace with the scientific breakthroughs like CRISPR and AI, while staying true to its core mission of assessing safety and effectiveness for consumers in the world of food and medicine.

with @vasnarasimhan @jorgecondebio @vijaypande @smc90 How does the world’s largest producer of medicines in terms of volume balance the science and  the business of innovation, from R&D to go to market to talent and more?

with @jorgecondebio and @smc90 A look-back and look-forward on the topic of personal genomics, given recent and past retrospective and prospective pieces in the media on the topics of DNA sequencing, personalized medicine, criminal investigations, genetic privacy and large datasets, multiomics, and more.

Kevin Kelly interviews Marc Andreessen at our most recent innovation Summit; they discuss the evolution of technology, key trends, and why they're the most optimistic people in the room.